<DOC>
	<DOCNO>NCT01253681</DOCNO>
	<brief_summary>To evaluate whether AMG 386 combination paclitaxel carboplatin safe well tolerated first-line treatment high-risk stage I stag II-IV epithelial ovarian , primary peritoneal fallopian tube cancer . The hypothesis AMG 386 combination carboplatin paclitaxel safe well tolerate .</brief_summary>
	<brief_title>Study AMG 386 Combination With Paclitaxel Carboplatin Subjects With Ovarian Cancer</brief_title>
	<detailed_description>To evaluate whether AMG 386 combination paclitaxel carboplatin safe well tolerated first-line treatment high-risk stage I stag II-IV epithelial ovarian , primary peritoneal fallopian tube cancer . The hypothesis AMG 386 combination carboplatin paclitaxel safe well tolerate .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Female subject 18 year age newly diagnose highrisk FIGO Stage I ( grade 3 , aneuploid grade 1 2 ) Stages IIIV epithelial ovarian , primary peritoneal fallopian tube cancer indication firstline treatment paclitaxel carboplatin x 6 cycle . Subjects pseudomyxoma , mesothelioma , adenocarcinoma unknown primary tumor , sarcoma , neuroendocrine histology exclude . Subjects highrisk stage I , stage II , stage IIIAB must prior primary debulking surgery occur less 4 week , 12 week , prior enrollment . Subjects must recover fully surgery opinion investigator Subjects Stage IIIC IV disease primary debulking surgery must plan interval debulking surgery follow 3 cycle AMG 386 , paclitaxel carboplatin Female 18 year age old time write informed consent obtain Subjects childbearing potential undergone bilateral salpingooophorectomy sexually active must consent use accepted effective nonhormonal method contraception ( i.e , double barrier method ( eg , condom plus diaphragm ) signing inform consent 6 month last dose study drug GOG Performance Status 0 1 Life expectancy ≥ 3 month ( per investigator opinion ) Subject plan begin protocoldirected therapy within 7 day enrollment Adequate organ hematological function evidence follow laboratory study prior enrollment : Hematological function , follow : Hemoglobin ≥ 9 g/dL Absolute neutrophil count ( ANC ) ≥ 1.5 x 10x9/L Platelet count ≥ 100 x 10x9/L ≤ 850 x 10x9/L PTT aPTT ≤ 1.5 x ULN per institutional laboratory range INR ≤ 1.5 Renal function , follow : Urinary protein quantitative value ≤ 30 mg/dL urinalysis ≤ 1+ dipstick , unless quantitative protein &lt; 1000 mg 24 hour urine sample Creatinine clearance &gt; 40 mL/min per 24hr urine collection calculate accord CockcroftGault formula Hepatic function , follow : AST ALT ≤ 2.5 x ULN per institutional laboratory range ( ≤ 5 x ULN liver metastasis present ) Total bilirubin ≤ 1.5x institution ' ULN Nutritional Albumin ≥ 2.8 g/dL Prior use anticancer therapy experimental therapy epithelial ovarian , primary peritoneal fallopian tube cancer Previous abdominal and/or pelvic external beam radiotherapy Subjects believe high average risk bowel perforation . This include current symptom partial complete bowel obstruction , recent ( within 6 month ) history fistula bowel perforation , subject require total parenteral nutrition continuous hydration History arterial venous thromboembolism within 12 month prior enrollment History clinically significant bleeding within 6 month prior enrollment History central nervous system metastasis Known active ongoing infection ( except uncomplicated urinary tract infection ) within 14 day prior enrollment Currently previously treat AMG 386 , molecule inhibit angiopoietins Tie2 receptor Current within 30 day prior enrollment treatment immune modulators systemic cyclosporine tacrolimus Prior myeloablative highdose chemotherapy allogeneic autologous stem cell ( bone marrow ) transplant Clinically significant cardiac disease within 12 month prior enrollment , include myocardial infarction , unstable angina , grade 2 great peripheral vascular disease , cerebrovascular accident , transient ischemic attack , congestive heart failure , arrhythmia control outpatient medication placement percutaneous transluminal coronary angioplasty/stent Uncontrolled hypertension define diastolic blood pressure &gt; 90 mmHg OR systolic blood pressure &gt; 140 mmHg . The use antihypertensive medication control hypertension permit Subjects history prior malignancy , except : Malignancy treat curative intent know active disease present ≥ 3 year prior enrollment felt low risk recurrence treat physician , Adequately treat nonmelanomatous skin cancer lentigo maligna without evidence disease Adequately treat cervical carcinoma situ without evidence disease Major surgery within 28 day prior enrollment still recover prior surgery Minor surgical procedure , include placement tunnel central venous access device , within 3 day prior enrollment History allergic reaction bacteriallyproduced protein Hypersensitivity paclitaxel drug use vehicle cremophor Pregnant ( ie , positive betahuman chorionic gonadotropin test ) breast feed plan become pregnant within 6 month end treatment Subject know positive test ( ) human immunodeficiency virus ( HIV ) infection , hepatitis C virus , acute chronic active hepatitis B infection Any condition investigator 's opinion make subject unsuitable study participation Any uncontrolled concurrent illness history medical condition may interfere interpretation study result Nonhealing wound , ulcer ( include gastrointestinal ) fracture Subject previously enrol onto study Subject available followup assessment Subject know sensitivity product administer dose Subject kind disorder compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>AMG 386</keyword>
	<keyword>Ovarian Cancer</keyword>
</DOC>